Gregory Fraser
Stock Analyst at Truist Securities
(3.26)
# 940
Out of 4,832 analysts
36
Total ratings
51.85%
Success rate
14.65%
Average return
Main Sectors:
Stocks Rated by Gregory Fraser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANIP ANI Pharmaceuticals | Maintains: Hold | $62 → $65 | $60.30 | +7.79% | 9 | Apr 21, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $220 → $230 | $106.59 | +115.78% | 1 | Mar 6, 2025 | |
| BHC Bausch Health Companies | Maintains: Hold | $8 → $7 | $4.56 | +53.51% | 2 | Jul 25, 2024 | |
| XAIR Beyond Air | Maintains: Buy | $10 → $8 | $0.18 | +4,233.69% | 6 | Apr 30, 2024 | |
| BTMD biote | Maintains: Buy | $10 → $9 | $3.97 | +126.99% | 2 | Jan 18, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Buy | $6 → $7 | $7.35 | -4.76% | 4 | Nov 8, 2023 | |
| CORT Corcept Therapeutics | Maintains: Hold | $26 → $29 | $70.84 | -59.06% | 5 | Aug 3, 2023 | |
| NVCR NovoCure | Reiterates: Buy | $95 | $17.12 | +455.07% | 3 | Jun 6, 2023 | |
| EOLS Evolus | Maintains: Buy | $14 → $18 | $10.01 | +79.82% | 2 | May 26, 2023 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $45 → $40 | $13.60 | +194.12% | 2 | May 26, 2023 |
ANI Pharmaceuticals
Apr 21, 2025
Maintains: Hold
Price Target: $62 → $65
Current: $60.30
Upside: +7.79%
Jazz Pharmaceuticals
Mar 6, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $106.59
Upside: +115.78%
Bausch Health Companies
Jul 25, 2024
Maintains: Hold
Price Target: $8 → $7
Current: $4.56
Upside: +53.51%
Beyond Air
Apr 30, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.18
Upside: +4,233.69%
biote
Jan 18, 2024
Maintains: Buy
Price Target: $10 → $9
Current: $3.97
Upside: +126.99%
Amneal Pharmaceuticals
Nov 8, 2023
Maintains: Buy
Price Target: $6 → $7
Current: $7.35
Upside: -4.76%
Corcept Therapeutics
Aug 3, 2023
Maintains: Hold
Price Target: $26 → $29
Current: $70.84
Upside: -59.06%
NovoCure
Jun 6, 2023
Reiterates: Buy
Price Target: $95
Current: $17.12
Upside: +455.07%
Evolus
May 26, 2023
Maintains: Buy
Price Target: $14 → $18
Current: $10.01
Upside: +79.82%
Arcutis Biotherapeutics
May 26, 2023
Maintains: Buy
Price Target: $45 → $40
Current: $13.60
Upside: +194.12%